Emmessar Biotech & Nutrition Ltd Stock Price Today (NSE: EMMESSA)

Emmessar Biotech & Nutrition Ltd

24.06+0.06 (+0.25%)
Market Closed

Fundamental Score

...

Emmessar Biotech & Nutrition Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Emmessar Biotech & Nutrition Ltd share price today is 24.06, up +0.25% on NSE/BSE as of 18 September 2026. Emmessar Biotech & Nutrition Ltd (EMMESSA) is a Small-cap company in the Commodity Chemicals sector with a market capitalisation of 12.02 (Cr). The 52-week high for EMMESSA share price is 42.75 and the 52-week low is 18.42. At a P/E ratio of 30.14x, EMMESSA is currently trading above its industry average P/E of 22.30x. The company has a Return on Equity (ROE) of 5.56% and a debt-to-equity ratio of 0.00.

Emmessar Biotech & Nutrition Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
27.70
Low
23.08
Volume
1.3K
Change
+0.49%

Emmessar Biotech & Nutrition Ltd share price chart: 0.49% return over the past month. 52-week high ₹42.75, 52-week low ₹18.42.

Emmessar Biotech & Nutrition Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
24.8424.8423.5724.6063.00 (Cr)
24.6924.6923.3923.601.17K (Cr)
24.8924.8923.1723.58386.00 (Cr)
24.9724.9724.0024.491.02K (Cr)
23.7524.6323.5924.62335.00 (Cr)
25.0025.0023.5223.75700.00 (Cr)
23.8424.7723.3124.72611.00 (Cr)
23.0825.9923.0823.776.49K (Cr)
25.9825.9823.1524.30781.00 (Cr)
27.7027.7023.7725.405.51K (Cr)

Emmessar Biotech & Nutrition Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
24.8527.7023.0824.60-1.01%
25.9825.9923.1124.38-6.16%
24.2128.0023.8025.34+4.67%
24.5027.3023.5024.70+0.82%
25.9527.9924.5024.77-4.55%
23.5027.9923.5026.47+12.64%
24.3028.7418.4223.56-3.05%
26.7032.6024.2925.91-2.96%
28.6730.9425.0025.40-11.41%
31.0132.4127.0029.35-5.35%
30.0033.3828.3232.11+7.03%
30.6234.4928.1131.03+1.34%

Returns & Performance

Poor

Return on Equity (ROE)

5.56%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

6.51%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

-170.55%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Emmessar Biotech & Nutrition Ltd Valuation Check

Poor

Price to Earnings (P/E)

30.14x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

22.30x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

59.53%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.19%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-24.07%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

-35.34%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

-44.44%

Compounded annual revenue growth over 5 years

Poor

EPS Growth (5-Year CAGR)

-21.22%

Earnings per share growth over 5 years

Poor

Net Profit Growth (5-Year CAGR)

-21.22%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.00x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

232.84x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

3.43 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Emmessar Biotech & Nutrition Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of EMMESSA across key market metrics for learning purposes.

Positive Indicators

5 factors identified

Debt-Free Balance Sheet (D/E: 0.00)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (232.84x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Healthy Liquidity Position (Current Ratio: 15.67)

Observation: Strong short-term liquidity to meet obligations.

Analysis: Current ratio >1.5 indicates good working capital management.

Balanced Promoter Holding (59.53%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

10 factors identified

Below-Average Return on Equity (5.56%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (6.51%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Margin Pressure Concerns (-170.55%)

Observation: Operating margins are below industry standards.

Analysis: OPM <5% may indicate pricing pressures or cost management challenges.

Profit Decline Concern (-24.07%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Revenue Contraction (-35.34%)

Observation: Sales decline may indicate market challenges or competitive pressures.

Analysis: Negative revenue growth requires analysis of market conditions.

Limited Growth History (-44.44% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

Weak Earnings Growth (-21.22% CAGR)

Observation: Below-average 5-year EPS growth performance.

Analysis: Low EPS growth may not keep pace with inflation.

Stagnant Profit Growth (-21.22% CAGR)

Observation: Limited 5-year profit growth trajectory.

Analysis: Low profit growth may indicate scalability challenges or market maturity.

Limited Institutional Interest (FII+DII: 0.19%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Emmessar Biotech & Nutrition Ltd vs Commodity Chemicals Peers

Peer Comparison - Commodity Chemicals

Compare Emmessar Biotech & Nutrition Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
26.3/100
24
₹12.02
30.1
Average
5.56%
Poor
6.51%
Poor
0.0
Excellent
-21.22%
Poor
-44.44%
Poor
0.00%
49.2/100
2520
₹74697.84
34.6
Average
0.00%
Poor
15.29%
Good
0.4
Excellent
9.70%
Good
13.45%
Good
0.32%
34.6/100
1358
₹17140.87
17.4
Average
11.27%
Average
12.57%
Average
0.8
Good
12.99%
Good
14.65%
Good
0.65%
16.3/100
603
₹15377.77
-8.86%
Poor
-3.24%
Poor
0.4
Excellent
2.85%
Average
7.41%
Good
1.58%
56.5/100
575
₹8446.62
8.1
Average
0.00%
Poor
10.62%
Average
0.0
Excellent
3.00%
Average
8.67%
Good
3.61%
56/100
3514
₹7010.03
103.6
Average
20.47%
Excellent
27.28%
Excellent
0.2
Excellent
32.34%
Excellent
36.90%
Excellent
0.18%
32.9/100
713
₹5232.97
78.8
Average
0.00%
Poor
1.58%
Poor
0.1
Excellent
12.40%
Good
2.66%
38.9/100
426
₹3927.50
7.6
Average
13.42%
Average
16.97%
Good
0.0
Excellent
7.70%
Good
1.11%
Average
2.75%
67.5/100
73
₹3609.71
22.0
Average
16.23%
Good
21.35%
Excellent
0.0
Excellent
19.92%
Excellent
14.48%
Good
0.63%
18.4/100
177
₹2796.83
0.00%
Poor
-3.82%
Poor
1.1
Average
2.14%
Average
0.00%
66.7/100
620
₹2427.57
32.3
Average
13.27%
Average
21.98%
Excellent
0.0
Excellent
23.80%
Excellent
17.52%
Excellent
0.23%

Emmessar Biotech & Nutrition Ltd PE Ratio History

Historical price-to-earnings ratio for EMMESSA — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20250.61₹29.3548.1x
FY 20241.48₹45.0430.4x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Emmessar Biotech & Nutrition Ltd Quarterly Performance

Latest quarterly metrics for EMMESSA — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

-35.34%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-24.07%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

-44.44%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

-21.22%

Compounded annual net profit growth over 5 years

Emmessar Biotech & Nutrition Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for EMMESSA — calculated from daily price history

51RSI 14
Neutral — RSI 51

Momentum is balanced — neither overbought nor oversold.

SMA 50
25
▼ Price below SMA 50 — Short-term bearish
SMA 200
26
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
1K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Emmessar Biotech & Nutrition Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Emmessar Biotech & Nutrition Ltd (EMMESSA) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Emmessar Biotech & Nutrition Ltd

Loading latest quarterly results...

About EMMESSA (Emmessar Biotech & Nutrition Ltd)

Emmessar Biotech & Nutrition Ltd is a dynamic player in the commodity chemicals sector, demonstrating a commitment to innovation and sustainable solutions. They source, manufacture..., and distribute a diverse range of essential chemical compounds that serve as vital building blocks for numerous industries. These chemicals are integral to producing everything from plastics and polymers that shape our everyday lives to advanced materials employed in construction and automotive manufacturing. EMMESSA prioritizes quality and consistency, ensuring that its products meet rigorous industry standards and customer expectations. This dedication translates into long-term partnerships with clients who rely on a dependable supply chain for their own manufacturing processes. By focusing on cost-effectiveness and operational efficiency, EMMESSA positions itself as a competitive and valuable partner in the commodity chemicals market. The company's strength lies in its robust infrastructure and a team of experienced professionals who possess deep knowledge of chemical processes and market dynamics. EMMESSA continuously invests in research and development, exploring innovative approaches to enhance product performance and minimize environmental impact. They are actively engaged in developing more sustainable alternatives and optimizing existing processes to reduce waste and energy consumption. The company’s commitment to responsible sourcing and ethical business practices ensures that its operations adhere to the highest standards of corporate social responsibility. This includes implementing strict safety protocols within its manufacturing facilities and actively participating in environmental conservation initiatives. EMMESSA's strategic approach to distribution and logistics allows them to efficiently serve a global customer base. Their network of strategically located warehouses and partnerships with reputable transportation providers ensures timely and reliable delivery of products to clients worldwide. Beyond simply supplying commodity chemicals, EMMESSA aims to be a trusted partner, offering technical expertise and support to help customers optimize their own production processes. This consultative approach strengthens customer relationships and fosters collaboration, contributing to the overall success of both EMMESSA and its clients. By focusing on customer satisfaction and continuous improvement, EMMESSA Biotech & Nutrition Ltd is poised for continued growth and success in the evolving commodity chemicals landscape.

Company Details

Symbol:EMMESSA
Industry:Commodity Chemicals
Sector:Commodity Chemicals

Key Leadership

Mr. Mathurakavi Srinivasa Raghavan Ayyangar
Founder, CEO, MD & Executive Chairman
Mr. Jeyavel Balaiah Nadar B.Com.
CFO, Executive Director & Internal Auditor
Ms. Priyanka Omprakash Sharma
Company Secretary & Compliance Officer

EMMESSA Share Price: Frequently Asked Questions

What is the current share price of Emmessar Biotech & Nutrition Ltd?

Emmessar Biotech & Nutrition Ltd (EMMESSA) trades at ₹24.06 on NSE and BSE. Market cap ₹12.02 (Cr). Educational data only.

What is the P/E ratio of Emmessar Biotech & Nutrition Ltd?

Emmessar Biotech & Nutrition Ltd has a P/E of 30.14x vs industry average 22.30x.

What is the Bull Run score for Emmessar Biotech & Nutrition Ltd?

Emmessar Biotech & Nutrition Ltd has a Bull Run score of 26.3/100 based on 25+ financial parameters.

Does Emmessar Biotech & Nutrition Ltd pay dividends?

Emmessar Biotech & Nutrition Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Emmessar Biotech & Nutrition Ltd?

Emmessar Biotech & Nutrition Ltd has ROE of 5.56%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Emmessar Biotech & Nutrition Ltd?

Emmessar Biotech & Nutrition Ltd has debt-to-equity of 0.00.

Is Emmessar Biotech & Nutrition Ltd a good investment?

Bull Run gives Emmessar Biotech & Nutrition Ltd a score of 26.3/100. This is not investment advice — consult a SEBI-registered advisor.